                         SEQUENCE LISTING

<110>  Arizona Board of Regents for the University of Arizona
       Hay, Meredith
       Konhilas, John
       Polt, Robin L.
 
<120>  ANG-(1-7) DERVIATIVE OLIGOPEPTIDES AND METHODS FOR USING AND 
       PRODUCING THE SAME

<130>  UAZ-000611PC

<150>  US 62/027,219
<151>  2014-07-21

<160>  13    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Derivative of Ang-(1-7)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  aspartic acid, glutamic acid, alanine or a derivative 
       thereof.

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  arginine, histidine, lysine, or a derivative thereof

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  valine, alanine, isoleucine, leucine, or a derivative 
       thereof.

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  tyrosine, phenylalanine, tryptophan, or a derivative 
       thereof.

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  isoleucine, valine, alanine, leucine, or a derivative 
       thereof.

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  histidine, arginine, lysine, or a derivative thereof.

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  proline, glycine, serine, or a derivative thereof.

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  can be absent or is serine, threonine, hydroxyproline, or a 
       derivative thereof

<400>  1

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  2
<211>  7
<212>  PRT
<213>  Homo sapiens

<400>  2

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-amino acids, C to N direction


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  D-amino acids in C to N direction

<400>  3

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L-amino acids in C to N direction


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  L-amino acids in C to N direction

<400>  4

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D-amino acids from N to C direction


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  D-amino acids from N to C direction

<400>  5

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino terminated carboxylic end


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  -OH of carboxylic acid terminal group is replaced with -NH2 
       group.

<400>  6

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  7
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivative


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  -OH of the carboxylic acid terminal is replaced with -NH2

<400>  7

Asp Arg Val Tyr Ile His Pro Ser 
1               5               


<210>  8
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivative


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Glucosylated and -OH of the carboxylic acid terminal end is 
       replaced with -NH2.

<400>  8

Asp Arg Val Tyr Ile His Pro Ser 
1               5               


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivative


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Lactosylated and -OH of the carboxylic acid terminal group is 
       replaced with -NH2.

<400>  9

Asp Arg Val Tyr Ile His Pro Ser 
1               5               


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivative


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Glucosylated and -OH of the terminal carboxylic acid end is 
       replaced with -NH2.

<400>  10

Asp Arg Val Tyr Ile His Ser 
1               5           


<210>  11
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivatives


<220>
<221>  MISC_FEATURE
<222>  (2)..(3)
<223>  Any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  May optionally be glucosylated or lactosylated and -OH of the 
       terminal carboxylic acid end is replaced with -NH2

<400>  11

Ala Xaa Xaa Tyr Ile Xaa Pro Ser 
1               5               


<210>  12
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivative


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  May optionally be glucosylated or lactosylated and -OH of the 
       terminal carboxylic acid end is replaced with -NH2

<400>  12

Asp Arg Xaa Tyr Xaa His Pro Ser 
1               5               


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ANG-(1-7) Derivative


<220>
<221>  MISC_FEATURE
<222>  (3)..(5)
<223>  Any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  May optionally be glucosylated or lactosylated and -OH of the 
       terminal carboxylic acid end is replaced with -NH2

<400>  13

Asp Arg Xaa Xaa Xaa His Pro Ser 
1               5               


